

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 March 2004 (11.03.2004)

PCT

(10) International Publication Number  
**WO 2004/019929 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/215**,  
47/00, 7/48

(21) International Application Number:  
PCT/IT2003/000530

(22) International Filing Date:  
2 September 2003 (02.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
BS2002A000078 2 September 2002 (02.09.2002) IT

(71) Applicant and

(72) Inventor: **DE PAOLI AMBROSI, Gianfranco** [IT/IT];  
Via Cure del lino 32, 25087 Salo' (Brescia) (IT).

(74) Agent: **SANGIACOMO, Fulvia**; Biesse S.R.L., Corso  
Matteotti, 42, I-25122 Brescia (IT).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,  
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,  
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: COMPOSITION BASED ON TRIETHYL CITRATE FOR THE TREATMENT OF BACTERIAL INFECTIONS OF  
THE SKIN

(57) Abstract: This invention concerns a composition for topical use containing as an active ingredient triethyl citrate either pure  
or in combination with synergists, and the pharmaceutical or cosmetic use of the composition, on its own or in association with an  
antibiotic, at least in the treatment of cutaneous pathologies directly or indirectly affected by bacterial infections.

WO 2004/019929 A1

"COMPOSITION BASED ON TRIETHYL CITRATE FOR THE TREATMENT  
OF BACTERIAL INFECTIONS OF THE CUTIS SKIN"

\* \* \* \*

Field of the invention

5 This invention concerns a new composition for cosmetic or  
pharmaceutical purposes, for external use, to be applied either on the cutis,  
whether integral or damaged, or on the mucous membrane, in order to  
improve all cutaneous pathologies both directly and indirectly affected by  
bacterial infections, such as for example superficial primary pyoderma and  
10 impetigo vulgaris and other common dermatitis infections, such as for  
example atopic dermatitis and the various forms of eczema.

State of the Art

Antibiotic therapy for topical use is used preferably in the  
dermatological field in that it allows the use of sufficient quantities of active  
15 principle in the area directly affected by the infectious process, avoiding the  
risks connected with systematic antibiotic therapy.

Triethyl citrate, that is a triethyl ester of citric acid, is well known and  
used in the cosmetic sector for the treatment of ageing of the skin (Patent US  
No. 5,686,489 dated 21 Nov. 1997), but it has never been either proposed or  
20 suggested as an active ingredient for the treatment of bacterial cutaneous  
infections, neither alone or in synergy with other substances.

Now, following specific research and experiments carried out by the  
inventor, it has become clear that the active ingredient, triethyl citrate taken  
into consideration herein, carries out an activity, comparable to and which can  
25 be placed over substances possessing antibiotic, antiseptic and disinfectant

activities, without generating bacterial resistance phenomena (on the contrary to the more common antibiotics).

### Objects and Summary of the Invention

This invention is based on the results of this research, and therefore its  
5 primary object is to propose the use of a new active principle useful at least in the cure of cutaneous pathologies involving infections having bacterial origins.

A further object of the invention is to provide an active principle for the formulation of products, both cosmetic and pharmaceutical, to be used locally in the treatment of cutaneous infections caused by bacteria, without producing  
10 bacterial resistance.

Yet another scope of the invention is to provide an active composition for the cure of cutaneous infections and which, advantageously, used in combination with antibiotics, antiseptics and disinfectants is able to prevent the setting in of bacterial resistance phenomena.

15 These aims are achieved, according to the invention, with a composition for cosmetic and pharmaceutical use containing triethyl citrate, as an active ingredient, pure or in association with synergists.

### Detailed Description of the Invention

In this invention and for the use given above, triethyl citrate may be  
20 used pure with suitable supports or vehicles, or better formulated with other chemical substances, such as synergists, additives and excipients as a percentage by weight from 0.1 to 99.9%, preferably from 0.5 to 50%, and better still from 5.0 to 15% on the basis of the final formulation, for both cosmetic and pharmaceutical preparations for local use.

25 Accordingly, the active ingredient represented by triethyl citrate can be

used, for example, in combination with substances which are part of the chemical group which include carboxylic acids, hydroxyacids, vitamins, amino acids, bioflavonoids, oligoelements, essential fatty acids and relative esters, antibiotics, sulphamides, disinfectants. Oleic, linolic and linolenic acid ethyl  
5 esters and other compounds such as for example erythromycin, clindamycin, metronidazole, gentamicin, fusidic acid, econazole, ketoconazole, mupirocin, hydrogen peroxide, benzoyl peroxide, cetylpyridinium, silver and relative salts, both organic and inorganic.

Synergists are understood to be for example: trans – retinal acid,  
10 retinol, retinaldehyde, tocopherol, ascorbic acid, p-aminobenzoic acid, rutin,  $\beta$ -Carotene, tiamin, riboflavin, pyridoxine, pyridoxale, niacin, nicotinic acid, nicotinamide, pantothenic acid, pantenol, glucosamine, aceylglucosamine, folic acid, lecithin, phosphlipids such as, for example phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, lyso-phosphatidylcholine,  
15 hydroquinone, oleic acid, linoleic acid, linolenic acid, ethyl oleate, ethyl linolenate, ethyl linoleate, Kojic acid, ascorbyl glucoside, erythromycin, clindamycin, metronidazole, gentamicin, fusidic acid, econazole, ketoconazole, mupirocin, neomocin, stretomicin, hydrogen peroxide, benzoil peroxide, cetylpyridinium, benzalkonium, chlorhexidin and relative salts and  
20 esters, silver and relative salts, both organic and inorganic, hydroxyacids and  $\beta$  hydroxyacids, both mono and bi carboxyls, such as glycolic acid, lactic acid (in the dextro and levorotatory forms and in racemic mixtures) hydroxybutyric acid (in the dextro and levorotatory forms and in racemic mixtures), mandelic acid (in the dextro and levorotatory forms and in racemic mixtures), tartaric  
25 acid (in the dextro and levorotatory forms and in racemic mixtures), malic acid

(in the dextro and levorotatory forms and in racemic mixtures), salicylic acid, 3-hydroxybenzoic acid, 4 - hydroxybenzoic acid, cysteine, acetyl cysteine, glycine, used singularly or in association with one or more including the relative salts, esters and amides and the relative D-L-DL forms.

- 5           The components of this group of substances can be used in association with triethyl citrate in a percentage by weight from 0.01% to 50% in weight, preferably from 0.5 to 15%.

          The following EXAMPLES of preparations illustrate even further the efficacy of the composition of this invention which contains triethyl citrate as  
10   an active ingredient.

          Triethyl citrate, possibly associated with appropriate synergists as described above, can be used in formulations for external use, such as a water emulsion in oil, oil emulsions in water, single phase solutions, dual phase pseudo-solutions, single phase gels, dual phase gels, anhydrous  
15   ointments and in powder form etc, using appropriate supports and vehicles.

EXAMPLES of preparations based on triethyl citrate base.

PREPARATION 1

No.	Description	
01	Triethyl citrate	100

Preparation method: use as it is

**PREPARATION 2**

No.	Description	
01	Triethyl citrate	20.00
02	Erythromycin	2.00
03	Ethyl alcohol	60.00
04	Deionised water	18.00

Preparation method: dissolve 02 in 03; mix 01 in the solution obtained; then add 04

**5 PREPARATION 3**

No.	Description	
01	Triethyl citrate	6.00
02	Salicylic acid	0.50
03	Ethyl alcohol	60.00
04	Deionised water	33.50

Preparation method: dissolve 02 in 03; mix 01 in the solution obtained; then add 04

**PREPARATION 4**

No.	Description	
01	Triethyl citrate	25.00
02	Retinic acid	0.025
03	Ppg – 15 stearyl ether –as needed	100

10 Preparation method: dissolve 02 in 03; mix 01 in the solution obtained;

**PREPARATION 5**

No.	Description	
01	Triethyl citrate	95.00
02	Ethyl linoleate	5.00

Preparation method: dissolve 02 in 01;

**PREPARATION 6**

No.	Description	
	<b>A)</b>	
01	Triethyl citrate	10,000
02	Steareth-2	3,000
03	Steareth-21	2,000
04	Vaseline oil	1,000
05	Stearic acid	5,000
	<b>B)</b>	
06	Preservatives	As needed
07	Glycerol	4,000
08	Deionised water	As needed 100

5

Preparation method: the ingredients (A) and ingredients (B) are heated separately at 70°C. Then ingredients (B) are added to ingredients (A) mixing until a well amalgamated mixture in the form of an emulsion for topical use is obtained.

**PREPARATION 7**

No.	Description	
01	Triethyl citrate	5,000
02	Chlorhexidine gluconate	0,250
03	Idrossietil cellulose	1,000
04	Deionised water as needed	100

Preparation method: dissolve 01 + 02 in 04; in the solution obtained disperse 03 until complete solvation and formation of a gel.



## CLAIMS

5           1. A composition for topical use for curing cutaneous pathologies, characterised in that it contains as an active ingredient triethyl citrate either pure or in combination with synergists.

          2. A composition according to claim 1, which contains triethyl citrate in a percentage by weight of 0.1 to 99.9. preferably from 5 to 50 percent.

10          3. A composition according to claim 2, which contains triethyl citrate in a percentage by weight of 5.0 to 50.0 percent.

          4. A composition according to any of the claims from 1-3, containing the active ingredient represented by triethyl citrate in association with at least one of the additional substances chosen between trans - retinal acid, retinol, 15 retinaldehyde, tocopherol, ascorbic acid, p-aminobenzoic acid, rutin,  $\beta$ -Carotene, tiamin, riboflavin, pyridoxine, pyridoxale, niacin, nicotinic acid, nicotinamide, pantothenic acid, pantenol, glucosamine, aceylglucosamine, folic acid, lecithin, phosphlipids such as, for example phosphatidylcholine, phosphatidylethanolamine, phosphatidic acid, lyso-phosphatidylcholine, 20 hydroquinone, oleic acid, linoleic acid, linolenic acid, ethyl oleate, ethyl linolenate, ethyl linoleate, Kojic acid, ascorbyl glucoside, erythromycin, clindamycin, metronidazole, gentamicin, fusidic acid, econazole, ketoconazole, mupirocin, neomocin, stretomicin, hydrogen peroxide, benzoil peroxide, cetylpyridinium, benzalkonium, chlorhexidin and relative salts and 25 esters, silver and relative salts, both organic and inorganic, hydroxyacids and

$\beta$  hydroxyacids, both mono and bi carboxyls, such as glycolic acid, lactic acid (in the dextro and levorotatory forms and in racemic mixtures) hydroxybutyric acid (in the dextro and levorotatory forms and in racemic mixtures), mandelic acid (in the dextro and levorotatory forms and in racemic mixtures), tartaric acid (in the dextro and levorotatory forms and in racemic mixtures), malic acid (in the dextro and levorotatory forms and in racemic mixtures), salicylic acid, 3-hydroxybenzoic acid, 4 - hydroxybenzoic acid, cysteine, acetyl cysteine, glycine, used singularly or in association with one or more including the relative salts, esters and amides and the relative D-L-DL forms.

10        5. A composition according to claim 4, wherein said additional substances are contained in a percentage by weight from 0.01% to 50%, preferably from 0.5 to 15%.

15        6. Use of a composition containing triethyl citrate according to any of the previous claims as a pharmaceutical substance at least for the treatment of cutaneous pathologies both directly and indirectly affected by infections of a bacterial origin.

7. Use according to claim 6 of a composition containing triethyl citrate in combination with an antibiotic for the treatment of cutaneous pathologies both directly and indirectly affected by infections of a bacterial origin.

20        8. Use of a composition containing triethyl citrate according to any of the claims from 1-5 as a cosmetic substance at least for the treatment of cutaneous blemishes both directly and indirectly caused by a bacterial component.

25        9. Method for the pharmaceutical or cosmetic cure of the skin including the procedures to use a composition containing triethyl citrate as an active

ingredient, either pure or in combination with synergists, to formulate said composition in a preparation for external use and to apply said preparation for a length of time and using a sufficient quantity on the skin for treatment of cutaneous pathologies directly or indirectly affected by infections of a bacterial origin such as, pyodermatitis, dermatitis, eczema and cutaneous blemishes  
5 caused by a bacterial component.